Approved labelSOLIQUA 100/33 label for the fixed-ratio insulin glargine and lixisenatide product
PopulationAdults covered by the approved SOLIQUA 100/33 indication
DoseThe pen starts at 15 dose-steps for patients naive to basal insulin or using less than 30 units, or 30 dose-steps for patients using 30-60 units of basal insulin. The maximum 60 dose-steps provides 60 units insulin glargine and 20 mcg lixisenatide.
RouteSubcutaneous injection in the abdomen, thigh, or upper arm
FrequencyOnce daily within the hour before the first meal
DurationLong-term use within the approved indication with label-directed titration
PreparationReady-to-use 3 mL prefilled pen containing 100 units/mL insulin glargine and 33 mcg/mL lixisenatide; no reconstitution and do not dilute or mix.